Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK looks to medical technology over high perinatal death rates:

This article was originally published in Clinica

Executive Summary

The current level of intrapartum-related deaths [in the UK] is unacceptable, and a renewed focus on clinical standards, research and audit is urgently needed." So says chief medical officer Sir Liam Donaldson in his report on the state of public health for 2006, of what he describes as a "seemingly intractable" situation. At 8.2 perinatal (ie stillbirths and early neonatal) deaths per 1,000 births - totalling 7,000 per year - the UK barely ranks at average levels for the developed world, and "considerably worse than North America and Australasia". The focus of his concerns is, more specifically, the death of the 500 or so babies annually who are apparently healthy during the start of labour for which the cause is not known. He is calling for "intensive research" to be carried out into these, as well as a review of all perinatal deaths - to help "elucidate the avoidable factors".

You may also be interested in...



Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib

Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel